Business
Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program
September 16 event to highlight preclinical data on the combination of FTI agents with multiple classes of targeted therapies October 18 event to review
About this update from Kura Oncology, Inc.
[{"type":"text","content":"September 16 event to highlight preclinical data on the combination of FTI agents with multiple classes of targeted therapies October 18 event to review clinical data from the ESMO Congress 2025, including first clinical data from KO-2806 SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for cancer, today announced it will host two virtual investor and analyst events to spotlight its innovative farnesyl transferase inhibitor (FTI) program. These events will underscore Kura’s leadership in targeting cancer signaling pathways to address unmet needs in solid tumors and hematologic malignancies. Event Details: FTI Preclinical Program Review: Synergistic Combinations with Targeted TherapiesTuesday, September 16, 20251:30 p.m. PT / 4:30 p.m. ETThis event will explore the scientific foundation, mechanisms of action and preclinical data supporting the combination of FTIs with tyrosine kinase inhibitors (TKIs), RAS inhibitors, and PI3K alpha inhibitors, highlighting their potential to transform treatment for solid tumors.Discussion of Clinical Data Presented at 2025 ESMO Congress, Including First Clinical Data from KO-2806, Kura’s Next-Generation FTISaturday, October 18, 202510:30 a.m. PT / 1:30 p.m. ETThis event will dive into clinical data presented at the 2025 European Society for Medical Oncology (ESMO) Congress, including the first clinical insights from KO-2806, Kura’s next-generation FTI, showcasing its potential to address resistance mechanisms in cancer. Live audio webcasts will be available in the Investors section of Kura’s website at https://kuraoncology.com/, with archived replays available following both events. Details of the presentations at ESMO Congress 2025 are as follows: Farnesyltransferase inhibitor (FTI) KO-2806 in combination with cabozantinib (cabo) in renal cell carcinoma (RCC): Preliminary results from FIT-001 phase 1 trialSaturday, October 18, 2025; 12:00 PM CESTPublication Number 2604P A phase 1 study of the next-generation farnesyltransferase inhibitor (FTI) KO-2806 as monotherapy in advanced solid tumors Sunday, October 19, 2025; 12:00 PM CESTPublication Number 981P Tipifarnib (TIP) and alpelisib (ALP) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): ...